近年血小板减少性紫癜文献分析

本文通过对1995-2003年有关血小板减少性紫癜文献年代分布、期刊分布、著者、文献主题词分布等方面进行统计分析,寻找其研究热点和发展趋势,为临床研究及治疗提供借鉴。     

The rheumatic poison: a survey of some published investigations of the immunopathogenesis of Henoch-Schönlein purpura

Laboratory studies of the pathophysiology of Henoch-Schönlein purpura (HSP) have become more numerous in recent years with the recognition of the disease's links with the mucosal immune system in general and IgA nephropathy in particular. There are weak genetic associations with C4 null phenotypes and with HLA B35 and DR4. Studies of plasma proteins in HSP patients show an increased IgA concentration, activation of the alternative pathway of complement and consumption of factor XIII. High molecular weight (polymeric) IgA has been detected in affected individuals, which some investigators have called immune complexes. Many patients synthesise an IgA rheumatoid factor in the acute phase, but other autoantibodies are largely absent. In vitro studies of lymphocytes from HSP patients have demonstrated an increased number of IgA-bearing and secreting B-cells, with altered T-cell regulation of antibody synthesis. While these observations point to immune dysregulation — primarily of IgA production — as a consistent feature of acute HSP, there is as yet insufficient information available to allow a consistent theory of pathogenesis to be formulated.     

Excretion of epidermal growth factor-like material in acute Henoch-Schönlein purpura nephritis

In Henoch-Schönlein purpura nephritis (HSPN), glomeruli may develop cellular crescents composed of infiltrating monocytes and proliferating renal epithelia. In this study, we demonstrate that peripheral human monocytes can release an epidermal growth factor (EGF)-like substance detectable by a radioreceptor assay, which recognizes both EGF and transforming growth factor-alpha (TGF-alpha), but not with a radioimmunoassay, which recognizes only EGF. Furthermore, we report that urine from pediatric patients during the acute phase of HSPN contains a similar EGF-like species in addition to the endogenous EGF which is normally present. The EGF-like material was not present in urine from nine healthy children or from six children with acute post-streptococcal glomerulonephritis. The extent of crescent formation in our patients is uncertain, since renal biopsy was performed in only one case. However, we speculate that the urinary material resembling TGF-alpha which appears during the acute phase of HSPN may derive from monocytes infiltrating the kidney.     

复方丹参与维生素C合用治疗过敏性紫癜32例

[背景 ]探讨过敏性紫癜的治疗方法 .[病例报告 ]应用复方丹参与维生素C合用治疗过敏性紫癜 32例 ,并辅以对症治疗 .结果 ,32例中显效 2 7例 ,有效 5例 ,总有效率为 10 0 % .[讨论 ]应用复方丹参及维生素C合用治疗过敏性紫癜疗效满意     

理血汤治疗慢性原发性血小板减少性紫癜的临床观察

目的 观察理血汤治疗慢性原发性血小板减少性紫癜（简称CITP）的临床疗效。方法 将CITP患随机分为理血汤治疗组（29例）和对照组（20例）。观察治疗前后外周血小板计数、血小板相关抗体、骨髓巨核细胞的变化。结果 治疗组和对照组的缓解率、显效率、总有效率分别为13.8%,24.1%.86.2%和5%,10%,60%。经统计学处理两组差异有非常显性（P＜0．01）,治疗组疗效明显优于对照组。停药后1个月治疗组外周血血小板计数仍明显高于对照组。结论 理血汤治疗CITP有较好疗效,具有很好的开发应用前景。     

ITP患者骨髓及血液检测指标与疗效关系的探讨

目的：为观察血小板表面相关抗体Ｇ（ＰａＩｇＧ）、外周血血小板计数（ＢＰＣ）、平均血小板容积（ＭＰＶ）、骨髓巨核细胞计数（ＭＫ）与产板型巨核细胞比例（ＰＰＭＫ）对特发性血小板减少性紫癜（ｉｄｉｏｐａｔｈｉｃ ｔｈｒｏｍｂｏｃｙｔｏｐｅｎｉｃｐｕｒｐｕｒａ,ＩＴＰ）患者疗效的预计价值。方法：采用Ｃｏｕｌｔｅｒ全自动血球分析仪及双抗体夹心ＥＬＩＳＡ法等,对７３例ＩＴＰ患者治疗前和治疗后的ＢＰＣ、ＭＰＶ、     

ITP患者脾动脉栓塞前后血小板的检测及其临床意义

应用自动血细胞计数仪检测ＩＴＰ患者脾动脉栓塞前后不同时期血小板的变化。结果栓塞后患者血小板计数（ＰＬＴ）和平均血小板体积（ＭＰＶ）的变化呈负相关,但ＰＬＴ恢复正常后,ＭＰＶ仍高于正常。提示脾动脉栓塞后血小板计数增高的机理不同于激素治疗。     

牛角地黄冲剂对大鼠免疫性血小板减少模型血浆血栓素A2、前列环素I2的实验研究

观察牛角地黄冲剂对大鼠免疫性血小板减少模型血栓素A2(TXA2)、前列环素I2(PGI2)的影响.将100只SD大鼠随机分成正常对照组、模型对照组、强的松对照组、牛角地黄冲剂高剂量组、牛角地黄冲剂低剂量组.除正常组外,各组均以注射免抗大鼠血小板血清(APS)造模,分别灌药和蒸馏水,每日1次,连续11天,分别在第7天和第11天各测一半大鼠血浆血栓素B2(TXB2)、6-酮-前列腺素F1α(6-keto-PGF1α)值,并作骨髓涂片检查.结果显示强的松组6-keto-PGF1α水平明显高于正常组水平(P＜0.05)而牛角地黄冲剂高剂量组6-keto-PGF1α浓度明显高于模型组,且接近正常组水平.而各组TXB2水平改变均不显著.说明牛黄地黄冲剂有改善ITP出凝血功能低下的作用,且不改变机体生理平衡.     

静脉丙种球蛋白加地塞米松治疗小儿特发性血小板减少性紫癜临床观察及护理

目的探讨静脉丙种球蛋白(IVIG)加地塞米松治疗小儿特发性血小板减少性紫癜(ITP)的疗效及护理。方法对34例ITP患儿随机分为激素组和静脉丙种球蛋白加地塞米松组(简称丙球组)。结果丙球组出血症状改善迅速，血小板上升时间、峰值时间较激素组明显缩短，两组比较差异有显著意义。结论静脉丙种球蛋白加地塞米松治疗TIP疗效显著。     

Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden

The frequency and treatment of children with chronic idiopathic thrombocytopenic purpura in Sweden were characterized using a national enquiry based on a questionnaire. Seventy-five children diagnosed as having chronic idiopathic thrombocytopenic purpura on 1 September 1993 were identified. The prevalence in children between 0.5 and 15.5 years of age was calculated to be 4.6/100 000. The median age at the time of diagnosis was 5 years and the male/female ratio was 1:1.2. Almost half of the patients (43%) were not treated at all during the disease. Steroids (43%) and intravenous immunoglobulin (25%) were most commonly used. Only two children were splenectomized.